The company also announced that the second patient has been dosed in the ongoing investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 for cystinosis. “The first patient dosed is an important
The primary endpoint of the SEP380-201 trial was the variation from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score after six weeks of treatment with SEP-4199. According
The study confirms the findings of the first pivotal study, demonstrating efficacy of treatment with daridorexant on objective and subjective sleep parameters and showed positive effects on daytime
APG-115 has been designed by Ascentage Pharma as an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. KEYTRUDA, on the other hand, is an anti-PD-1 therapy, which
Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6,
Patients with TNBC, an aggressive subtype of breast cancer, have limited treatment options beyond standard chemotherapy. High TROP2 expression has been reported in up to 80 percent of
CONTACT-02 is part of a clinical trial collaboration between Exelixis and Roche that includes two additional phase 3 pivotal trials – CONTACT-01 in patients with metastatic non-small cell
The Series B round of Goldfinch Bio was led by Eventide Asset Management. It also included new investors – Wellington Management Company, Ally Bridge Group, Casdin Capital, funds
Some patients with AHRF can progress to a more severe form of the disease called acute respiratory distress syndrome (ARDS). ARDS, which is associated with lung inflammation leading
Duvroq is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, which is yet to be approved for any indication anywhere else in the world with the exception of Japan.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.